07:00 , Jun 29, 2009 |  BC Week In Review  |  Clinical News

Trofex: Phase I data

Data from a single-blind, crossover, U.S. Phase I trial in 5 patients with metastatic prostate cancer showed that a pair of radiolabeled small molecules, MIP-1072 and MIP-1095, detected metastatic tumors with similar target to background...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Clinical News

Molecular Insight preclinical data

In human prostate cancer cells, MIP-1072 demonstrated high affinity and specific binding to prostate-specific membrane antigen ( PSMA). MIP-1072 and MIP-1095, a fellow radio-labeled molecular imaging agent targeting PSMA, are in a Phase I...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Clinical News

Molecular Insight preclinical data

In human prostate cancer cells, MIP-1095 demonstrated high affinity and specific binding to prostate-specific membrane antigen ( PSMA). MIP-1095 and MIP-1072, a fellow radio-labeled molecular imaging agent targeting PSMA, are in a Phase...
07:00 , Jul 24, 2008 |  BC Innovations  |  Tools & Techniques

Imaging Prostate Cancer Metastasis

Determining the status of lymph node metastasis in prostate cancer is important for deciding treatment options, but current techniques for detecting metastasis are imprecise and invasive. A paper published in Nature Medicine describes a noninvasive...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Clinical News

Trofex: Phase I started

Molecular Insight began a single-blind, crossover, U.S. Phase I trial to evaluate a pair of radiolabeled small molecules, MIP-1072 and MIP-1095, in up to 12 patients who have evidence of recurrent metastatic prostate cancer....
08:00 , Mar 4, 2002 |  BC Week In Review  |  Clinical News

Xanelim anti-CD11a: Phase III

Pooled data from 1095 patients in 2 Phase III trials showed that 29% and 28% of patients treated for 12 weeks with 1 mg/kg and 2 mg/kg of Xanelim, respectively, had a 75% PASI improvement...